Think Mylan's done with M&A after its Pfizer deal? Think again

Mylan expects to close its Upjohn merger in mid-2020. (Mylan on YouTube)

Mylan is focused on closing its merger with Pfizer's Upjohn next year. But after that deal closes, the pumped-up company should have the firepower for more M&A to beef up its business further, an exec said. 

Asked about a "fragmented" generics market on a Tuesday conference call, Mylan CFO Ken Parks said he sees an opportunity to build on the combined company’s commercial presence and strike more deals after the merger. 

Set to debut in 2020, the new company will outline its own strategies, Parks said, but he believes the opportunity for M&A is there. 


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The statements came as Mylan reported third-quarter revenues of $2.96 billion, a 3% increase versus the same period last year. The company’s adjusted earnings per share for the quarter fell 6% to $1.17. Mylan and Upjohn are set to close their deal in mid-2020.

While Mylan suffered from increased competition and an ongoing Morgantown restructuring that cost $58 million in the third quarter, new launches so far generated $800 million in 2019. Overall for the year, Mylan expects $1 billion in revenues from its newly rolled-out products.  

RELATED: Here's how Pfizer's reorg and Mylan's identity crisis yielded a giant generics merger 

As execs push to close the big merger, Mylan has also been cleaning out its own pantry. The generics maker discontinued 350 products that made no “business rationale” to sell, Mylan President Rajiv Malik said on Tuesday’s call. While the moves will result in lower revenues, the discontinuations won't affect profits, he said.

Going forward, the portfolio review will be an “ongoing” process, Malik said, but Mylan doesn’t expect a “bolus” like the previous batch that it recently discontinued.  


Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.